To identify whether TAK1 inhibitor 5Z-7 could inhibit NF-κB pathway and thereby block NF-κB activation-induced chemoresistance, we treated a panel of five cervical cancer cell lines, including HeLa, C-33-A, Ca Ski, ME-180 and SiHa, with Dox, a NF-κB activator, and the TAK1 inhibitor 5Z-7 for 48 h (Figure 2A). This evidence concerns the gene NFKB1 and cervical cancer.